CHMP, Rekkirona Province, available for emergency use in individual European countries
viewer
Celltrion’s new coronavirus infection (Corona 19) antibody treatment’Rekirona’ was opened in Europe to supply individual countries.
The European Medicines Agency (EMA) Drug User Advisory Committee (CHMP) announced on its website on the 26th that it has completed a review on the use of Rekirona in patients with COVID-19.
EMA reviewed the effects of Rekyrona in mild and moderate Corona19 patients who did not require oxygen therapy, and expressed an opinion that individual European countries in an urgent need to introduce antibody treatments could use Rekirona in an emergency. The CHMP concluded that Rekyrona could be considered one of the treatments for high-risk patients or patients with severe exacerbation. This means that Celltrion will be able to supply Rekirona to individual European countries prior to formal approval.
In terms of safety, EMA said most of the side effects of Rekirona were mild or moderate. However, EMA added, “While Rekirona may lower hospitalization rates, it is not robust enough to reach a solid conclusion at this point,” he added, adding that further observation by medical staff is needed. On the other hand, the evaluation regarding the official approval of Rekirona, which began on February 24, is still ongoing.
/ Reporter Ji-hye Seo [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >